Works matching IS 2160763X AND DT 2015 AND VI 4 AND IP 2

Results: 13

Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 137, doi. 10.1002/cpdd.145

By:

Cotreau, Monette M.;
Siebers, Nicholas M.;
Miller, James;
Strahs, Andrew L.;
Slichenmyer, William

Publication type:

Article

Issue Information.

Published in:: 2015
Publication type:: Other

Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy participants.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 155, doi. 10.1002/cpdd.140

By:

Shumaker, Robert;
Aluri, Jagadeesh;
Fan, Jean;
Martinez, Gresel;
Thompson, Gary A.;
Ren, Min

Publication type:

Article

A soft benzodiazepine.

Published in:

2015

By:

Greenblatt, David J.

Publication type:

Editorial

The effects of the nonselective benzodiazepine lorazepam and the α2/α3 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 149, doi. 10.1002/cpdd.134

By:

te Beek, Erik T.;
Chen, Xia;
Jacobs, Gabriël E.;
Nahon, Kimberly J.;
de Kam, Marieke L.;
Lappalainen, Jaakko;
Cross, Alan J.;
van Gerven, Joop M. A.;
Hay, Justin L.

Publication type:

Article

Pharmacokinetics of single and repeat doses of icatibant.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 105, doi. 10.1002/cpdd.138

By:

Leach, J. Kevin;
Spencer, Kelly;
Mascelli, Maryann;
McCauley, Thomas G.

Publication type:

Article

Effects of icosapent ethyl (Eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of rosiglitazone in healthy subjects.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 143, doi. 10.1002/cpdd.150

By:

Braeckman, Rene A.;
Stirtan, William G.;
Soni, Paresh N.

Publication type:

Article

Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 83, doi. 10.1002/cpdd.171

By:

Krishnaswami, Sriram;
Boy, Mary;
Chow, Vincent;
Chan, Gary

Publication type:

Article

Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 121, doi. 10.1002/cpdd.174

By:

Zack, Julia;
Berg, Jolene;
Juan, Axel;
Pannacciulli, Nicola;
Allard, Martine;
Gottwald, Mildred;
Zhang, Heather;
Shao, Yongwu;
Ben‐Yehuda, Ori;
Jochelson, Phil

Publication type:

Article

An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 112, doi. 10.1002/cpdd.175

By:

Leese, Philip T.;
Trang, John M.;
Blum, Robert A.;
de Groot, Eleanor

Publication type:

Article

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 89, doi. 10.1002/cpdd.176

By:

Wang, Diane D.;
Li, Chunze;
Sun, Wan;
Zhang, Shuzhong;
Shalinsky, David R.;
Kern, Kenneth A.;
Curtin, Nicola J.;
Sam, Wai‐Johnn;
Kirkpatrick, Tanya R.;
Plummer, Ruth

Publication type:

Article

A comparative pharmacokinetic and pharmacodynamic study of FSK0808 versus reference filgrastim after repeated subcutaneous administration in healthy Japanese men.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 99, doi. 10.1002/cpdd.178

By:

Matsuguma, Kyoko;
Matsuki, Shunji;
Sakamoto, Kei;
Shiramoto, Masanari;
Nakagawa, Misato;
Kimura, Miyuki;
Irie, Shin;
Kaneko, Daiki;
Ohnishi, Akihiro

Publication type:

Article

Intravenous pharmacokinetics, local tolerability, and hemolysis of an SBE7-β-cyclodextrin formulation of the neurokinin-1 receptor antagonist vestipitant.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 130, doi. 10.1002/cpdd.128

By:

Brigandi, Richard A.;
Russ, Steven F.;
Petit, Chantal;
Johnson, Brendan;
Croy, Scott;
Hodsman, Peter;
Muller, Fran

Publication type:

Article